A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

Key facts

Sponsor

Cascade Pharmaceuticals, Inc

Principal Investigator

Ma Xiong, MD

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Intervention

2mg CS0159(drug)

Enrollment

135 target

Eligibility

18-75 years · All sexes

Timeline

2025 – 2028

Study locations (30)

• The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China
• The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
• Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing Municipality, China
• Beijing Youan Hospital, Capital Medical University, Beijing, Beijing Municipality, China
• China-Japan Friendship Hospital, Beijing, Beijing Municipality, China
• Chongqing University Three Gorges Hospital, Chongqing, Chongqing Municipality, China
• The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
• Mengchao Hepatobiliary Hospital Of Fujian Medical University, Fuzhou, Fujian, China
• Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
• Shenzhen Third People's Hospital, Shenzhen, Guangdong, China
• Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
• The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
• Hebei Medical University Third Hospital, Shijiazhuang, Hebei, China
• The Fourth Hospital Of Harbin Medical University, Harbin, Heilongjiang, China
• Henan Provincial People's Hospital, Zhengzhou, Henan, China
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary biliary cholangitis

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07449793
  Biochemical Response and Clinical Outcomes in Patients With PBC
  RenJi Hospital
• RECRUITINGPHASE3NCT07296458
  FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
  Xijing Hospital of Digestive Diseases
• RECRUITINGNCT07205874
  Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)
  Hospital Universitario La Paz
• ACTIVE NOT RECRUITINGNCT07049887
  A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)
  Ipsen
• RECRUITINGNCT07149675
  PBC Long-term Outcomes Study
  Beijing Friendship Hospital
• RECRUITINGEARLY PHASE1NCT07104201
  Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)
  Xijing Hospital of Digestive Diseases
• RECRUITINGNANCT06861465
  EMPower Mechanisms
  University of Alberta
• RECRUITINGNANCT07161245
  RELIEF: Multimodal Prehabilitation to Treat Fatigue in Patients With Primary Biliary Cholangitis
  Hospital Clinic of Barcelona

See all trials for Primary biliary cholangitis →